Cargando…

End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab

Detalles Bibliográficos
Autores principales:	Magro, Giuseppe, De Martino, Antonio, Tosto, Federico, Santangelo, Domenico, Manzo, Lucia, Bruno, Pietro, Pascarella, Angelo, Pasquale, Marilisa, Barone, Stefania, Gambardella, Antonio, Valentino, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498491/ http://dx.doi.org/10.1016/j.jns.2021.118177

Ejemplares similares

Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic
por: Magro, Giuseppe, et al.
Publicado: (2022)

Myositis associated to COVID-19 mimics an acute exacerbation in myasthenia gravis patient
por: De Martino, Antonio, et al.
Publicado: (2021)

A case of neuromyelitis optica spectrum disorder (NMOSD) and acute myositis following SARS-CoV-2 infection
por: Barone, Stefania, et al.
Publicado: (2021)

A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide
por: Mumoli, Laura, et al.
Publicado: (2013)

Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
por: Bringeland, Gerd Haga, et al.
Publicado: (2020)

Edis on Sterility in Women
Publicado: (1891)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

EDI200 therapeutic trial
por: Huttner, Kenneth
Publicado: (2012)

EDI OCT evaluation of choroidal thickness in Stargardt disease
por: Sodi, Andrea, et al.
Publicado: (2018)

CD4 cell response to interval therapy with natalizumab
por: Berkovich, Regina, et al.
Publicado: (2015)

The circular RNA Edis regulates neurodevelopment and innate immunity
por: Xiong, Xiao-Peng, et al.
Publicado: (2022)

The implementation of Electronic Data Interchange at CERN (EDI)
por: Ferguson, J, et al.
Publicado: (1990)

BizTalk 2013 EDI for health care
por: Beckner, Mark
Publicado: (2014)

Incomplete Susac syndrome exacerbated after natalizumab
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2015)

EDItEUR EDI manual: Electronic Data Interchange
por: United Nations Economic Commission for Europe. Geneva. EDItEUR, et al.
Publicado: (1995)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach
por: Borriello, Giovanna, et al.
Publicado: (2020)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
por: Pelle, Juliette, et al.
Publicado: (2023)

Equity, Diversity and Inclusion (EDI) in Organ Transplantation: An ESOT Survey About EDI Within ESOT as an Organization and its Educational Activities, and Transplantation Research and Science
por: Pengel, L. H. M., et al.
Publicado: (2023)

Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)
por: Nour, Matthew M., et al.
Publicado: (2016)

Reference values for diaphragm electrical activity (Edi) in newborn infants
por: Gurumahan, Varappriyangga, et al.
Publicado: (2022)

Intersectionality, health equity, and EDI: What’s the difference for health researchers?
por: Kelly, Christine, et al.
Publicado: (2022)

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

Highlight report: The EDI3-GPAM axis in tumor cell migration
por: Hassan, Reham
Publicado: (2017)

Optic disc drusen in children: morphologic features using EDI-OCT
por: Teixeira, Filipa Jorge, et al.
Publicado: (2019)

BizTalk 2010 EDI for health care: HIPAA compliant 837 solutions
por: Beckner, Mark
Publicado: (2013)

EDI3 links choline metabolism to integrin expression, cell adhesion and spreading
por: Lesjak, Michaela S, et al.
Publicado: (2014)

Choroidal thickness using EDI-OCT in adult-onset vitelliform macular dystrophy
por: Palácios, Renato Menezes, et al.
Publicado: (2016)

The European Diploma in Radiology (EDiR): investing in the future of the new generations of radiologists
Publicado: (2018)

Psychometric Properties of the Eating Disorder Inventory-3 (EDI-3) in Chilean Youth
por: Lizana-Calderón, Paula, et al.
Publicado: (2022)

Network-based validation of the psychometric questionnaire EDI-3 for the assessment of eating disorders
por: Punzi, Clara, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities
por: Marchan, Rosemarie, et al.
Publicado: (2012)

Choroidal Thickness Analysis in Patients with Usher Syndrome Type 2 Using EDI OCT
por: Colombo, L., et al.
Publicado: (2015)

EDI3, a key enzyme of choline metabolism controls tumour cell migration
por: Marchan, Rosemarie, et al.
Publicado: (2012)

A circular RNA Edis-Relish-castor axis regulates neuronal development in Drosophila
por: Liu, Wei, et al.
Publicado: (2022)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_6k55eljs618s1hbr2ljmfl0ria